

This document is scheduled to be published in the Federal Register on 03/23/2016 and available online at http://federalregister.gov/a/2016-06479, and on FDsys.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

NATIONAL CANCER INSTITUTE Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2); notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c) (4) and 552b(c) (6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel

Feb2016 Cycle 22 NExT SEP Committee Meeting

Date: April 27, 2016

Time: 8:30 AM to 4:30 PM

Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.

Place: National Institutes of Health

9000 Rockville Pike

Campus Building 31, Conference Room 6C10

Bethesda, MD 20892

(Telephone Conference Call)

Contact Person: Barbara Mroczkowski, PhD

Executive Secretary

Discovery Experimental Therapeutics Program

National Cancer Institute, NIH 31 Center Drive, Room 3A44

Bethesda, MD 20817 (301) 496-4291

(301) 490-4291

mroczkoskib@mail.nih.gov

Toby Hecht, PhD
Executive Secretary
Development Experimental Therapeutics Program
National Cancer Institute, NIH
9609 Medical Center Drive, Room 3W110
Rockville, MD 20850
(240) 276-5683
toby.hecht2@nih.gov

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page:

http://deainfo.nci.nih.gov/advisory/fac/fac.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated:March 17, 2016	_
Melanie J. Gray, Program Analyst Office of Federal Advisory Committee Polic	<u> </u>

[FR Doc. 2016-06479 Filed: 3/22/2016 8:45 am; Publication Date: 3/23/2016]